Analysis Tools
growth/size/body
 |
• untreated mice show decreased body weight
|
homeostasis/metabolism
|
|
• STZ-treated mice show lower serum triglycerides than treated wild-type mice
|
|
|
• mice show attenuation of the development of nephropathy in streptozotocin (STZ)-induced diabetes, showing a delay in the development of albuminuria, renal protection with an early reduction in mesangial expansion and attenuation of glomerular hypertrophy at 16 weeks, less pronounced podocyte loss and reduction in cortical TGFB1 expression at 8 weeks
• however, STZ-treated mice develop diabetes and show similar elevations of plasma glucose, loss of body weight, kidney hypertrophy, glomerular hyperfiltration, and systolic blood pressure as wild-type mice
|
renal/urinary system
|
|
• podocyte numbers per glomerulus are lower in untreated mice
|
